首页> 外文期刊>Trends in Peptide and Protein Sciences >Identification of Proteins Participating in the Cisplatin Resistance Following Treatment with Cisplatin in A2780 and A2780CP Ovarian Cell Lines
【24h】

Identification of Proteins Participating in the Cisplatin Resistance Following Treatment with Cisplatin in A2780 and A2780CP Ovarian Cell Lines

机译:在A2780和A2780CP卵巢细胞系中与顺铂治疗中参与顺铂抗性的蛋白质的鉴定

获取原文
       

摘要

Ovarian cancer is the most fatal gynecological cancer and the 8 th most prevalent type of cancer in Iran. Chemotherapy regimen for the treatment of this type of cancer is mostly based on platinum agents and paclitaxel. The major problem during treatment with cisplatin is the appearance of acquired resistance in cancer cells in the first 6 months of therapy. Owing to inefficacy of second line regimens, it seems necessary to find out the molecular mechanisms of cisplatin resistance and find an efficient strategy against the resistant cancer cells. In this study, two ovarian cancer cell lines, A2780-sensitive and A2780CP (resistant to cisplatin) were evaluated. To acquire the protein expression profile, a culture of each line containing 1.5×10 7 cells was divided into the two groups of control and treatment cells. The treatment group cells were treated with cisplatin at pre-determined IC 50 concentration for 6 hours. Then, the total proteins of 7×10 6 cells were extracted. The proteome of each group (20 μg) was used for subsequent separation of proteins by two-dimensional gel electrophoresis using 7 cm IPG strips. The results of protein pattern changes were analyzed by one-way ANOVA. At least 230 proteins were detected in each gel, from which, about 45 proteins were differentially expressed in each model of comparison. However, by considering the results of all models of analysis on the protein expression profile of two cell lines, three proteins were determined as the key players of resistance against cisplatin. Our results can be considered in the therapeutic regimen of ovarian cancers with cisplatin as important knowledge for defending against resistant cancer cells. HIGHLIGHTS The major problem during treatment with cisplatin is the appearance of acquired resistance in cancer cells. The cisplatin- resistant and sensitive ovarian cell lines of A2780 were evaluated in this study. Proteomics analysis was run using 2D gel electrophoresis after cisplatin treatment. Three proteins were determined as the key players of resistance against cisplatin in A2780 cell line.
机译:卵巢癌是伊朗最致命的妇科癌症和第8种最普遍的癌症类型。用于治疗这种类型癌症的化疗方案主要基于铂族代理和紫杉醇。用顺铂治疗期间的主要问题是在治疗的前6个月内癌细胞中获得性抗性的出现。由于二线方案的低效率,似乎有必要找出顺铂抗性的分子机制,并找到抗抗性癌细胞的有效策略。在该研究中,评估了两种卵巢癌细胞系,A2780敏感和A2780CP(对顺铂耐药)。为了获得蛋白质表达谱,将含有1.5×10 7个细胞的每条线的培养物分成两组对照和处理细胞。在预定的IC 50浓度下用顺铂处理处理组细胞6小时。然后,提取7×10 6细胞的总蛋白质。每组(20μg)的蛋白质组用于随后通过使用7cmG IPG条带通过二维凝胶电泳分离蛋白质。通过单向ANOVA分析蛋白质模式变化的结果。在每个凝胶中检测到至少230个蛋白质,在每个凝胶中,在每个比较模型中差异表达约45个蛋白质。然而,通过考虑两种细胞系的蛋白质表达谱的所有分析模型的结果,将三种蛋白质确定为对顺铂的抗性的关键球员。我们的结果可以考虑在卵巢癌的治疗方案中,顺铂作为防止抗性癌细胞的重要知识。突出含有顺铂治疗期间的主要问题是癌细胞中获得性抗性的外观。在本研究中评估了A2780的顺铂抗性和敏感的卵巢细胞系。在顺铂处理后使用2D凝胶电泳进行蛋白质组学分析。三种蛋白质被确定为A2780细胞中对顺铂抗性的关键球员。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号